Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Nov 04, 2021 11:55am
220 Views
Post# 34087126

RE:RE:RE:RE:RE:News out on Goblet trial with Merck

RE:RE:RE:RE:RE:News out on Goblet trial with MerckWow, now 10B would be a dream come true for all but realistically what is wrong with 2-3 billion (20 -30 times our market cap now) and let someone else run the ship. We do not know if someone has actually made a solid real offer or not and onc is not going to tell. Honestly we have biomarkers, successful aware1 data and really all results have been good to date and we have collaborations with a lot of the bigs (as does everyone) so what is the holdup and why no institutions knocking on the door.
Is there something that we are not aware of. Will the bracelet be the be all end all or will be now need something else to confirm. And will onc please tell us if Adalai is using the bio-markers as this is supposedly what all the delays were about. There would be no reason for them not to. simple yes or no question .

<< Previous
Bullboard Posts
Next >>